Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC.
Investor insights
Funding rounds participated in
$225M sweet spot round size
Investor type
Basic info
Industry
Sectors
Date founded
1998
Funding rounds raised
Total raised
$225M
from investors over 1 rounds
Array BioPharma Inc. raised $225M on October 14, 2017